Clinical Differences Between Severe and Non-Severe Preeclampsia
The term "severe preeclampsia" should not be used in clinical practice according to current international guidelines, as all cases of preeclampsia may become emergencies rapidly and should be managed with equal vigilance. 1
Key Guideline Position
The International Society for the Study of Hypertension in Pregnancy (ISSHP) explicitly recommends abandoning the clinical distinction between "mild" and "severe" preeclampsia because:
- All preeclampsia cases carry risk of rapid deterioration regardless of initial presentation 1
- Blood pressure levels alone do not reliably stratify immediate risk, as serious organ dysfunction (renal impairment, neurological complications) can develop at relatively mild BP levels 1
- The classification creates a false sense of security that can delay appropriate monitoring and intervention 1
Historical "Severe Features" (For Understanding Context Only)
While guidelines discourage this terminology, understanding what was historically labeled "severe" helps identify high-risk situations requiring immediate intervention:
Maternal Indicators of Critical Status:
- BP ≥160/110 mm Hg (surrogate marker for stroke risk and overall disease severity) 1
- Neurological manifestations: severe intractable headache, repeated visual scotomata, eclampsia 1
- Elevated cerebral perfusion pressure (>52% in historically "severe" cases vs. normal in 87% of "mild" cases), which may cause barotrauma and hypertensive encephalopathy 2
- Thrombocytopenia (progressive platelet decline) 1
- Liver dysfunction: elevated transaminases, HELLP syndrome 1, 3
- Renal impairment: progressive creatinine elevation 1, 3
- Pulmonary edema 1, 3
Hemodynamic Differences:
- Elevated systemic vascular resistance occurs in all preeclampsia phenotypes 4
- Lower cardiac output specifically characterizes cases with fetal growth restriction and early-onset disease 4
- Combined high systemic vascular resistance Z-score and abnormal uterine artery Doppler shows 95% sensitivity and 80% specificity for predicting progression to critical status 4
Fetal/Placental Indicators:
- Placental abruption 1
- Reversed end-diastolic flow on umbilical artery Doppler 1
- Non-reassuring fetal status 1
- Small-for-gestational-age with lower stroke volume 4
Practical Management Approach
All Preeclampsia Cases Require:
- Hospital assessment at diagnosis 1
- BP monitoring with treatment threshold ≥140/90 mm Hg, targeting diastolic BP of 85 mm Hg 1
- Twice-weekly blood tests: hemoglobin, platelets, liver transaminases, creatinine, uric acid 1
- Clinical assessment including clonus evaluation 1
- Fetal monitoring: biometry, amniotic fluid, umbilical artery Doppler at diagnosis, then every 2 weeks if normal 1
Immediate Delivery Indications (Regardless of Initial Severity):
- ≥37 weeks gestation 1, 5
- Inability to control BP despite ≥3 antihypertensive classes 1
- Progressive thrombocytopenia or deteriorating liver/renal function 1
- Ongoing neurological features 1
- Maternal pulse oximetry <90% 1
- Placental abruption or fetal compromise 1
Magnesium Sulfate Prophylaxis:
- Indicated for: proteinuria with severe hypertension, OR hypertension with neurological signs/symptoms 1
- Also for preeclampsia with "severe features" (≥34 weeks gestation) 6
Critical Pitfalls to Avoid
- Do not use BP level alone to determine admission or monitoring intensity—organ dysfunction can occur at any BP 1
- Do not delay intervention waiting for "severe" criteria—rapid deterioration is unpredictable 1
- Do not use serum uric acid or proteinuria level as delivery indications—these do not correlate with timing 1
- Do not attempt expectant management beyond 37 weeks—delivery reduces maternal morbidity without increasing neonatal risk 5
Long-term Implications
Women with any preeclampsia phenotype face increased lifelong cardiovascular risk (chronic hypertension, ischemic heart disease, heart failure, vascular dementia, end-stage renal disease), requiring postpartum counseling about long-term medical follow-up 5, 7